A Positive Deviance Approach for Representing Women, Older Adults and Patients Identifying as Racial and Ethnic Minorities in Oncology Research

OMB Control No. 0910-0847 Expiration Date: 2/28/2026

A Positive Deviance Approach for Representing Women, Older Adults and Patients Identifying as Racial and Ethnic Minorities in Oncology Research

Paperwork Reduction Act Statement: According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a valid OMB control number. The time required to complete this information collection is estimated to average one minute per response, including the time for completing the screen questions, testing the interview link, logging onto the online platform, reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information.

Send comments regarding this burden estimate or any other aspects of this collection of information, including suggestions for reducing burden to PRAStaff@fda.hhs.gov.

The study we are conducting is on behalf of the U.S. Food and Drug Administration (FDA).

Email subject: Seeking administrators and staff for interviews on clinical trial diversity

Dear <participant name>,

We are seeking volunteers to participate in a one-hour interview for a research study called A positive deviance approach to representing women, older adults and patients identifying as racial and ethnic minorities in oncology research.

Please reply to this message to indicate whether you are interested in participating, by Zoom, and if so we will contact you with further information and for scheduling.

If you have any questions concerning the research study, please contact Jennifer Miller at Jennifer.e.miller@yale.edu.

Thank you for considering sharing your expertise on the topic of demographic representation in cancer drug development.

Sincerely,

Jennifer Miller, PhD